Clinical observation of Tiaoganlipi decoction combined with S-1 capsule in the treatment of advanced primary liver cancer patients
-
摘要: [目的]探讨调肝理脾方联合替吉奥胶囊治疗晚期原发性肝癌患者的临床效果。[方法]采用回顾性研究方法，2011年2月~2014年8月选择在我院诊治的晚期原发性肝癌患者98例作为研究对象，根据治疗方法的不同分为中药组60例与常规组38例，常规组给予基于替吉奥胶囊的化疗方案治疗，中药组在常规组治疗的基础上给予调肝理脾方治疗，记录与随访2组近远期预后情况。[结果]中药组与常规组的治疗总有效率分别为66.7%和42.1%，中药组的治疗总有效率明显高于常规组（P<0.05）。2组毒副反应主要为血液毒性反应、肝肾功能异常、消化道反应、神经系统反应等，2组毒副反应情况比较差异无统计学意义（P>0.05）。治疗后中药组与常规组的KPS评分分别为（78.13±4.24）分和（69.14±5.10）分，都明显高于治疗前的（57.24±6.19）分和（58.14±7.30）分（P<0.05），且治疗后中药组的KPS评分明显高于常规组（P<0.05）。中药组的6个月与1年生存率分别为91.7%和66.7%，都明显高于常规组的71.1%和50.0%（P<0.05）。[结论]调肝理脾方联合替吉奥胶囊治疗晚期原发性肝癌患者能提高治疗疗效，不增加毒副反应的发生，改善临床功能症状，延长远期生存时间，有很好的应用价值。Abstract: [Objective] To investigate the clinical effect of Tiaoganlipi decoction combined with S-1 capsule in the treatment of advanced primary liver cancer patients.[Methods] From February 2011 to August 2014, 98 patients with advanced primary liver cancer in our hospital for treatment were selected as the research object, all the patients were divided into 2 groups according to the different treatment methods, Chinese medicine group of 60 patients and 38 patients of normal group.The normal group was treated with chemotherapy of S-1, while the Chinese medicine group was added Tiaoganlipi treatment based on the treatment in control group.Recent and long-term prognosis was recorded.[Results] The total effective rate of the Chinese medicine group and the normal group were 66.7% and 42.1% respectively, and the total effective rate of the Chinese medicine group was significantly higher than that of the normal group(P<0.05).The toxicity of the two groups were mainly in the blood toxicity, liver and kidney function abnormalities, gastrointestinal reactions, nervous system reactions.The two groups of adverse reactions were not significantly different(P>0.05).After the treatment, KPS scores in the Chinese medicine group and the normal group were 78.13±4.24 points and 69.14±5.10 points, which were significantly higher than that before treatment of 57.24± 6.19 points and 58.14±7.30 points(P<0.05), and the KPS score in the Chinese medicine group after treatment was significantly higher than the control group(P<0.05).The 6 months and 1 year survival rates of the traditional Chinese medicine group were 91.7% and 66.7%, respectively, which were significantly higher than those of the normal group of 71.1% and 50.0%(P<0.05).[Conclusion] Tiaoganlipi decoction combined with S-1 capsule in the treatment of advanced primary liver cancer patients can improve the curative effect.It does not increase the side reaction, can improve the clinical symptoms of function, prolong the survival time of the long-term and has good application value.
-
Key words:
- Tiaoganlipifang /
- s-1 capsule /
- advanced hepatocellular carcinoma /
- toxicity /
- survival rate
-
-
[1] 黎汉忠, 黄智芬, 张作军, 等.健脾消积汤治疗肝癌癌因性疲乏的临床疗效观察[J].中医临床研究, 2016, 8(10):18-20.
[2] Dong Y, Wu G.Analysis of short and long term therapeutic effects of radiofrequency hyperthermia combined with conformal radiotherapy inhepatocellular carcinoma[J].J BUON, 2016, 21:407-411.
[3] Bano S, Nazir S, Nazir A, et al.Microwave-assisted green synthesis of superparamagnetic nanoparticles using fruit peel extracts:surface engineering, T 2relaxometry, and photodynamic treatment potential[J].Int J Nanomedicine, 2016, 10:3833-3848.
[4] 周玉平, 张华, 慕永平, 等.从虚损生积论治肝癌[J].中医杂志, 2016, 57(2):170-172.
[5] Mansur C, Pfeiffer ML, Esmaeli B.Evaluation and Management of Chemotherapy-Induced Epiphora, Punctal and Canalicular Stenosis, and Nasolacrimal Duct Obstruction[J].Ophthal Plast Reconstr Surg, 2016, 7:9222-9228.
[6] 史国军, 叶兴涛, 陆宁, 等.健脾柔肝方联合替吉奥胶囊治疗晚期原发性肝癌患者30例临床观察[J].中医杂志, 2016, 57(8):677-681.
[7] 霍丹, 王继红, 张小丽, 等.原发性肝癌治疗的病例报告1例[J].中国肝脏病杂志(电子版), 2014, 12(2):68-69.
[8] Zhang B, Moser MA, Zhang EM, et al.Study of the relationship between the target tissue necrosis volume and the target tissue size in livertumours using twocompartment finite element RFA modelling[J].Int JHyperthermia, 2014, 30:593-602.
[9] 丘恺, 李明, 裴晓宁, 等.替吉奥胶囊联合沙利度胺治疗晚期原发性肝癌24例[J].医药导报, 2014, 33(2):221-223.
[10] 桑泽杰, 王华明, 纪卫政, 等.巴塞罗那肝癌分期B期、C期原发性肝癌患者肝动脉灌注化疗栓塞术后长期口服低剂量替吉奥的疗效观察[J].中国全科医学, 2015, 11(27):3324-3327.
[11] Tomioku M, Yazawa N, Furukawa D, et al.Repeated Hepatectomy for Recurrent Intrahepatic Cholangiolocellular Carcinoma:Report of a Case[J].Tokai J Exp Clin Med, 2016, 41:92-96.
[12] Katano A, Yamashita H, Okuma K, et al.Complete response to abdominal bulky lymph node recurrence in an esophageal cancer patient treated with S-1 monotherapy:A case report[J].Oncol Lett, 2016, 11:3901-3903.
[13] 郭晓光, 王虎明.替吉奥联合TACE序贯肝动脉灌注奥沙利铂治疗转移性肝癌的临床研究[J].中国临床研究, 2015, 28(5):559-562.
[14] Kano K, Sato T, Maezawa Y, et al.A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy[J].Gan To Kagaku Ryoho, 2016, 43:1262-1264.
[15] 李明, 裴晓宁, 张成辉.替吉奥胶囊联合沙利度胺治疗晚期原发性肝癌的临床观察[J].中国社区医师(医学专业), 2012, 14(17):51-56.
[16] 刘淑红.奥沙利铂联合替吉奥胶囊治疗晚期原发性肝癌的临床研究[J].实用医技杂志, 2012, 19(4):350-351.
[17] Huang W, You L, Yang S, et al.Metronomic S-1chemotherapy plustranscatheter arterial chemoembolization(TACE):apromising treatment of hepatocellular carcinoma refractory to TACE[J].J BUON, 2016, 21:909-916.
[18] 张呈, 陈昌南, 林云笑, 等.替吉奥与沙利度胺联合肝动脉栓塞化疗治疗中晚期肝细胞癌的临床观察[J].现代肿瘤医学, 2015, 2(17):2475-2478.
[19] Fujimoto T, Ohtsuka T, Date K, et al.Expression of Bcl-2 19-kDa interacting protein 3predicts prognosis after ampullary carcinoma resection[J].J Hepatobiliary Pancreat Sci, 2016, 23:489-496.
[20] 余小红, 娄继滨, 晏继喜, 等.替吉奥持续低剂量口服联合小剂量TACE治疗原发性肝癌疗效观察[J].重庆医学, 2015, 13(24):3367-3369.
[21] Hara T, Etoh T, Ueda Y, et al.A case of undifferentiated-type mucosal gastric cancer with multiple lymph node metastases fulfilling the curative criteria for endoscopic resection according to routine pathological analysis[J].Surg Case Rep, 2016, 2:96-105.
-
计量
- 文章访问数: 105
- PDF下载数: 44
- 施引文献: 0
下载: